English
Quicking Biotech Launches Rapid Point-of-Care Diagnostic with CE Mark Approval
Created on 07.13
Quicking Biotech Launches Rapid Point-of-Care Diagnostic with CE Mark Approval
For Immediate Release
Introduction: A New Era in Rapid Point-of-Care Diagnostic Testing
Quicking Biotech Co., Ltd., a recognized leader in the field of rapid diagnostic solutions, has officially announced the receipt of CE Mark approval for its latest innovation—the QuickScreen SARS-CoV-2 Antigen Rapid Test. This significant regulatory milestone paves the way for the company to market this advanced point-of-care diagnostic across the European Union and other regions that recognize the CE Marking as a benchmark for product safety, health, and environmental compliance. The test is designed to deliver reliable results in just 15 minutes, making it an invaluable tool for healthcare professionals working in hospitals, clinics, and community testing centers who need rapid answers to guide patient management decisions. With high sensitivity and specificity metrics that rival laboratory-based methods, this new diagnostic kit represents a leap forward in accessible and accurate testing technology. The company anticipates that this product will play a critical role in ongoing public health efforts by enabling faster identification of infections and reducing the burden on centralized laboratory infrastructure.
Beyond the technical achievement, this launch underscores Quicking Biotech’s broader mission to democratize access to high-quality diagnostic tools that can be deployed in diverse clinical environments. The QuickScreen test is built on a lateral flow immunoassay platform, a well-established technology that offers simplicity, speed, and reliability without the need for complex instrumentation or extensive training. For healthcare providers who have long relied on traditional laboratory testing and even scheduled a quest diagnostics appointment for confirmatory results, this point-of-care alternative provides an opportunity to reduce wait times dramatically and initiate treatment protocols much earlier in the patient care pathway. The CE Mark approval not only validates the test's performance but also signals to distributors and healthcare systems across Europe that Quicking Biotech is a trusted partner in the fight against infectious diseases.
The Significance of CE Mark Approval for Diagnostic Products
Obtaining CE Mark approval is a rigorous process that requires manufacturers to demonstrate that their products meet stringent European Union safety, health, and environmental protection requirements. For a diagnostic device like the QuickScreen SARS-CoV-2 Antigen Rapid Test, this involves comprehensive clinical evaluations, performance studies, and quality management system audits to ensure consistent manufacturing standards. The CE Mark allows the product to be freely marketed and circulated within the European Economic Area, giving healthcare providers access to a new generation of rapid diagnostic tools that have been independently verified for accuracy and reliability. This approval is particularly meaningful for Quicking Biotech because it reflects the company’s commitment to aligning its product development processes with international regulatory frameworks, which is essential for building trust among clinicians, distributors, and public health authorities. The designation also facilitates easier market access in other regions that recognize CE Marking as a gold standard for medical device quality, thereby expanding the potential reach of the QuickScreen test well beyond Europe.
From a practical standpoint, the CE Mark approval means that hospitals and clinics can now integrate the QuickScreen test into their routine diagnostic workflows with confidence, knowing that the product has passed rigorous scrutiny. This is especially important in point-of-care settings where decisions about patient isolation, treatment, and discharge must be made quickly and accurately. The availability of a CE-marked rapid diagnostic reduces the uncertainty that often accompanies unverified testing products and provides a clear regulatory pathway for procurement and reimbursement. Furthermore, the approval positions Quicking Biotech as a serious contender in the European diagnostic market, which is known for its high standards and competitive landscape. By achieving this milestone, the company demonstrates that its research and development capabilities, manufacturing quality, and regulatory expertise are on par with the best in the industry, opening doors for future product launches and deeper partnerships across the continent.
Technical Specifications and Clinical Performance of the QuickScreen Test
The QuickScreen SARS-CoV-2 Antigen Rapid Test is a lateral flow immunoassay designed to detect the presence of viral antigens in nasopharyngeal swab samples collected from individuals suspected of having a respiratory infection. The test procedure is straightforward: a healthcare professional collects a nasopharyngeal swab, inserts it into an extraction buffer vial, and then dispenses a few drops of the treated sample onto the test cassette. Results are read visually after 15 minutes, with one line indicating a negative result and two lines indicating a positive result for the presence of viral antigens. The test has demonstrated a clinical sensitivity of 96.7% and a specificity of 99.1% in controlled studies, which means it correctly identifies the vast majority of true positive cases while maintaining an extremely low false-positive rate. These performance metrics are comparable to many laboratory-based molecular assays, making the QuickScreen test a reliable alternative for settings where access to polymerase chain reaction (PCR) testing is limited or where rapid turnaround is critical for patient management decisions.
In addition to its strong analytical performance, the QuickScreen test has been designed with usability in mind, featuring clear instructional materials, stable reagents, and a robust cassette format that minimizes the risk of handling errors. The test does not require any specialized equipment, electricity, or cold chain storage, which makes it suitable for deployment in remote or resource-limited settings where traditional laboratory infrastructure may be unavailable. For healthcare professionals who routinely rely on a combination of diagnostic methods—including diagnostic imaging and, in some cases, sonograms to assess respiratory complications—having a rapid antigen test that can be performed at the bedside adds a valuable layer of clinical information that supports more comprehensive patient evaluations. The QuickScreen test fills a specific niche in the diagnostic ecosystem by providing immediate, actionable results that complement the insights gained from imaging studies and other clinical assessments, ultimately leading to more informed and timely treatment decisions.
Transforming Point-of-Care Diagnostics in Hospital and Clinic Settings
The introduction of the QuickScreen SARS-CoV-2 Antigen Rapid Test represents a meaningful advancement in the field of point-of-care diagnostics, particularly for healthcare facilities that serve high volumes of patients with respiratory symptoms. In emergency departments, urgent care centers, and outpatient clinics, the ability to obtain a reliable diagnostic result within 15 minutes can significantly streamline patient flow, reduce overcrowding in waiting areas, and help healthcare workers allocate resources more efficiently. Rather than sending samples to a central laboratory and waiting hours or even days for results—or requiring patients to schedule a quest diagnostics appointment for follow-up testing—clinicians can now make real-time decisions about isolation precautions, antiviral therapy, and hospital admission based on a test result that is available before the patient leaves the examination room. This immediacy not only improves the patient experience by reducing anxiety and uncertainty but also enhances infection control practices by enabling faster identification and containment of contagious individuals.
Moreover, the QuickScreen test is designed to be used by healthcare professionals with minimal training, which lowers the barrier to adoption in a wide range of clinical environments. The test does not require complex sample preparation, expensive instrumentation, or specialized laboratory skills, making it an ideal solution for community health centers, mobile testing units, and primary care practices that may not have access to advanced diagnostic infrastructure. For patients who might otherwise need to travel to a dedicated testing facility or wait for an appointment at a major diagnostic laboratory, the availability of rapid testing at their local clinic represents a significant improvement in convenience and access to care. By reducing reliance on centralized testing models and empowering frontline providers with immediate diagnostic capabilities, Quicking Biotech is helping to create a more resilient and responsive healthcare system that can adapt to fluctuating demand during respiratory illness seasons and public health emergencies alike.
Strategic Market Rollout and Distribution Across Europe
Quicking Biotech has announced that the initial rollout of the QuickScreen SARS-CoV-2 Antigen Rapid Test will focus on key European markets, leveraging a network of established distributors who specialize in supplying diagnostic products to hospitals, clinics, and public health institutions. The company has selected distribution partners based on their expertise in regulatory compliance, cold chain logistics, and customer support, ensuring that the test reaches end users in optimal condition and with appropriate training materials. The rollout strategy includes a phased approach, beginning with countries that have expressed strong demand for rapid testing solutions and progressing to additional markets as distribution capacity expands. Quicking Biotech is also working closely with its distributors to provide technical training, marketing collateral, and post-market surveillance support, which are essential for building long-term relationships with healthcare customers and maintaining the highest standards of product quality and safety.
Beyond the immediate European focus, the company sees the CE Mark approval as a springboard for broader international expansion, including potential entry into markets in Asia, Latin America, and the Middle East where rapid diagnostic testing is increasingly prioritized by healthcare systems. The QuickScreen test's favorable performance characteristics, ease of use, and competitive pricing position it well for adoption in both public and private healthcare settings. Distributors and healthcare procurement organizations are already expressing interest in evaluating the test for use in national testing programs, occupational health screening, and travel-related testing requirements. As Quicking Biotech continues to invest in its manufacturing capacity and supply chain resilience, the company is well positioned to scale production rapidly in response to growing demand, ensuring that healthcare providers have reliable access to this important diagnostic tool. The company also plans to complement the QuickScreen test with a range of related products, including multiplex assays and digital readout solutions, to further enhance the value proposition for its distribution partners and end users.
About Quicking Biotech: A Legacy of Innovation in Diagnostics
Quicking Biotech Co., Ltd., established in 2005, has built a strong reputation as a developer and manufacturer of high-quality rapid diagnostic products for a variety of applications, including infectious disease testing, food safety screening, and veterinary diagnostics. With nearly two decades of experience in the industry, the company has developed a deep understanding of the technical and regulatory challenges associated with bringing diagnostic products to market, as well as the evolving needs of healthcare professionals and patients around the world. The company's research and development team works continuously to innovate across multiple technology platforms, including lateral flow immunoassays, immunochromatographic assays, and rapid test formats that prioritize speed, accuracy, and usability. Quicking Biotech's manufacturing facilities are equipped with advanced production lines and quality control systems that ensure consistent product performance across millions of test kits produced annually, and the company holds several certifications that attest to its commitment to quality management and regulatory compliance.
The company's mission is to make diagnostic testing more accessible, affordable, and actionable for people everywhere, and the CE Mark approval for the QuickScreen SARS-CoV-2 Antigen Rapid Test is a direct reflection of that mission in action. Quicking Biotech believes that no patient should have to wait too long for a diagnosis, and no clinician should have to make critical decisions without reliable data. By combining scientific rigor with practical design, the company creates diagnostic solutions that work effectively in the real-world conditions of busy healthcare settings. Looking ahead, Quicking Biotech is committed to expanding its product portfolio to address emerging infectious diseases, antimicrobial resistance, and other pressing global health challenges. The company's leadership team, comprising experienced professionals from the diagnostic, pharmaceutical, and medical device sectors, provides strategic direction and operational excellence that position Quicking Biotech for sustained growth and impact in the years to come.
Frequently Asked Questions (FAQ)
What is the QuickScreen SARS-CoV-2 Antigen Rapid Test and how does it work?
The QuickScreen SARS-CoV-2 Antigen Rapid Test is a point-of-care diagnostic that uses a lateral flow immunoassay to detect viral antigens from a nasopharyngeal swab sample, providing results in 15 minutes. A healthcare professional collects the sample, mixes it with an extraction buffer, and applies a few drops to the test cassette, where a visible line indicates a positive or negative result. The test is designed for use in hospitals, clinics, and other healthcare settings to support rapid clinical decision-making.
How accurate is the QuickScreen diagnostic test compared to PCR testing?
The QuickScreen test has demonstrated a clinical sensitivity of 96.7% and a specificity of 99.1% in validation studies, meaning it correctly identifies most true positive cases and has a very low false-positive rate. While PCR testing remains the gold standard for molecular detection, the QuickScreen test offers comparable accuracy for antigen detection and provides the advantage of much faster turnaround times without the need for laboratory equipment.
What does CE Mark approval mean for this rapid diagnostic product?
CE Mark approval indicates that the QuickScreen test meets the European Union's stringent requirements for safety, health, and environmental protection under the In Vitro Diagnostic Directive. This regulatory clearance allows the product to be marketed and sold across the European Economic Area and is recognized as a mark of quality and reliability by healthcare providers and distributors worldwide.
Can the QuickScreen test be used alongside diagnostic imaging or sonograms?
Yes, the QuickScreen test complements diagnostic imaging modalities such as chest X-rays and sonograms by providing rapid etiological confirmation of a suspected respiratory infection. While imaging studies help assess the extent of lung involvement or complications, the QuickScreen test identifies the specific viral cause, enabling more targeted treatment decisions and improved patient management in clinical settings.
How does this point-of-care diagnostic compare to scheduling a quest diagnostics appointment for testing?
The QuickScreen test offers results within 15 minutes at the point of care, eliminating the need for patients to travel to a centralized laboratory or wait days for results after a quest diagnostics appointment. This speed allows clinicians to make immediate decisions about isolation, treatment, and discharge, which improves patient flow and reduces the burden on healthcare facilities during high-demand periods.
Who is authorized to administer the QuickScreen diagnostic test?
The QuickScreen test is authorized for use by healthcare professionals, including physicians, nurses, and trained medical staff in hospital and clinic settings. The test procedure is straightforward and requires minimal training, making it accessible to a wide range of clinical personnel who are responsible for patient assessment and infection control.
What sample type is required for the QuickScreen SARS-CoV-2 Antigen Rapid Test?
The test is designed for use with nasopharyngeal swab samples collected by a healthcare professional. This sample type is widely used for respiratory virus detection and provides a high concentration of viral antigens, which contributes to the test's strong sensitivity and specificity performance in clinical evaluations.
Where will the QuickScreen test be available for purchase and distribution?
Initial distribution is focused on European markets through a network of authorized distributors who specialize in diagnostic products for hospitals, clinics, and public health institutions. Quicking Biotech plans to expand availability to additional regions over time, including Asia, Latin America, and the Middle East, as distribution partnerships and regulatory approvals are secured.
What is Quicking Biotech's experience in the diagnostic industry?
Founded in 2005, Quicking Biotech Co., Ltd. has nearly 20 years of experience in developing and manufacturing rapid diagnostic products for infectious disease testing, food safety, and veterinary applications. The company operates advanced production facilities, holds multiple quality certifications, and has a proven track record of bringing reliable diagnostic solutions to markets around the world.
How can healthcare facilities or distributors request more information about the QuickScreen test?
Healthcare facilities and distributors can contact Quicking Biotech directly via email at info@quickingbiotech.com or by phone at +86-XXX for product inquiries, pricing, and distribution opportunities. Additional information is also available on the company's Products page, and updates are posted regularly on the News page.
###
Contact
Leave your information and we will contact you.
